PhoreMost applies its proprietary SITESEEKER technology to advance the discovery of novel targets in oncology and Targeted Protein Degradation.

PhoreMost

PhoreMost Ltd | 5,276 followers on LinkedIn. Drugging the Undruggable® | PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases.

Investor at BGF

Tim Rea

Partner @ Amadeus Capital

Pierre Socha

Associate Director of Drug Discovery at PhoreMost Ltd

Miguel Coelho

CEO at PhoreMost Ltd

Neil Torbett

PhoreMost Ltd

📢 A rational approach to molecular glue discovery: GlueSEEKER™ Molecular glues are an emerging class of innovative drug that exploit the cell’s proteostasis mechanisms by inducing close proximity between a target protein and an effector protein (like an E3 ligase). This effectively glues them together. These small molecule drugs have so far only been discovered by serendipity. To address this challenge, we have developed GlueSEEKER. Expanding on our SITESEEKER platform, GlueSEEKER integrates computational approaches with molecular biology to systematically identify new molecular glue targets, expanding the scope for this important modality and helping us to bring new precision medicines to fruition faster. Learn more on our website: https://rb.gy/o2vyjf

We had a great time at the TPD and Induced Proximity Summit, hearing about the latest advances in molecular glues, degrader therapeutics, and novel protein degradation mechanisms, as well as sharing updates on our internal pipelines. Didn’t manage to catch our presentations? Contact us to learn more about our innovative approaches to drug discovery: 📩 info@phoremost.com 💻 www.phoremost.com #TPD #MolecularGlues #DegraderTherapeutics

This week, Dr Neil Torbett and Dr Ian Hutchison are in Stockholm for #BIOEurope Autumn, meeting with leaders from across the life science industry to discuss the latest opportunities for collaborative innovation. Interested in learning more about how we are enabling the discovery of novel degrader therapeutics? Get in touch to schedule a meeting: info@phoremost.com #TPD #DrugDiscovery #LifeScience

“The next decade promises further innovation, particularly with the rational design of molecular glues” Dr Benedict CS Cross , CTO, spoke with The Medicine Maker and provided insight exploring innovations in molecular glues and how they will improve therapeutic outcomes by overcoming pharmacokinetic limitations of bivalent degraders and expanding the druggable space. 📰 Read the full article: https://lnkd.in/ecQSjFuE #MolecularGlues #DrugDiscovery #Innovation

Our team has arrived in Boston for the TPD and Induced Proximity Summit! Be sure to catch our presentations: Neil Torbett , CEO 🎤 Visions for the future of TPD and Beyond: the CEO perspective 🎤 CEO Think Tank: a strategic look at TPD and induced proximity field Christian Dillon , CSO 📆 30th Oct, 11:30am EDT 🎤 Discovery of Bifunctional Degraders Operating Through the CUL1/SKP1 SCF Complex Benedict CS Cross , CTO 📆 31st Oct, 1:30pm EDT 🎤 A Systematic Protein Editing Platform to Unlock Molecular Glue Discovery #TPD #MolecularGlues #DegraderTherapeutics

💡 A brilliant idea for helping cancer patients is just that – an idea – until it is put into practice. This latest article from University of Cambridge explores 10 of its spinouts changing the story of cancer, including PhoreMost. Being based in Cambridge allows us to be supported by the University’s innovation arm, Cambridge Enterprise , which is engaging with academics, entrepreneurs, and venture funds to drive the development of more effective and targeted oncology therapeutics. Read more: https://lnkd.in/eFsBQGcf #Oncology #DrugDevelopment #ChangingTheStoryOfCancer

📢 Join our team! Are you an innovative Computational Chemist looking for an exciting new opportunity in small molecule drug discovery? We’re recruiting for a Senior/Principal Computational Chemist to join our Drug Discovery team, based in our labs at Unity Campus Cambridge. Responsibilities include: 🧪 Onboarding new methodologies to be integrated into our platform 🧪 Providing computational chemistry support for the design of high-quality molecular glue and PROTAC molecules 🧪 Supporting the Target Discovery team with protein modelling Find out more and apply: https://lnkd.in/gt8gd9-i #CambridgeJobs #DrugDiscovery #ComputationalChemistry

Introducing 10 Cambridge spinouts changing the story of cancer. 🌟 A brilliant idea for helping cancer patients is just that - an idea - until it is put into practice. Turning research into something that can improve patient outcomes and benefit healthcare systems around the world is not easy. At Cambridge Enterprise, we support spinouts from the University of Cambridge through their commercialisation journey. Being part of the UK’s leading life sciences cluster provides plenty of inspiration, access to investors and talent, and the guidance of others who have gone before. Meet 10 of our spinouts, all committed to making a real difference: • T-Therapeutics Ltd • Concr • 52North - creators of Neutrocheck® • PhoreMost Ltd • STORM Therapeutics Limited • Verinnogen • Spirea • biomodal • PharmEnable Therapeutics • Astex Pharmaceuticals 👉🏼 Read more about how they are are driving the future of cancer treatment: https://vist.ly/3mj67du #CancerResearch #Healthcare #LifeSciences #UniversityOfCambridge #Innovation

Cambridge Enterprise

Not long to go until the TPD and Induced Proximity Summit! Our team has a busy schedule of presentations and panel discussions planned, including: Neil Torbett , CEO 📆 29th Oct, 8:15am EDT 🎤 Visions for the future of TPD and Beyond: the CEO perspective 📆 29th Oct, 9:30am EDT 🎤 CEO Think Tank: a strategic look at TPD and induced proximity field Christian Dillon , CSO 📆 30th Oct, 11:30am EDT 🎤 Discovery of Bifunctional Degraders Operating Through the CUL1/SKP1 SCF Complex Benedict CS Cross , CTO 📆 31st Oct, 1:30pm EDT 🎤 A Systematic Protein Editing Platform to Unlock Molecular Glue Discovery Find out more here: https://lnkd.in/ezfvZeeF #TPD #MolecularGlues #DrugDiscovery

Thank you Business Weekly newspaper for including us in the latest Life Science Killer50 list! The list celebrates Cambridge’s most innovative life science companies, reflecting the exciting potential of our SITESEEKER and GlueSEEKER platforms to develop the next generation of degrader therapeutics. Find out more on our website: www.phoremost.com #DrugDiscovery #TPD #MolecularGlues

Metric
Company Name	PhoreMost
Symbol
MSH ID	COM:PHOREMOST
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	GB
Stage
Employee Count
Website	phoremost.com
LinkedIn	phoremost
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

PHOR

COM:PHOREMOST

PhoreMost

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue